Search research articles
Contact Us
Filters
Showing results (21-30 of 77) with videos related to
Page
of 8
Sort By:
Journal of Adolescent and Young Adult Oncology
|
July 15, 2024
Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults
Nicole P Daukshus, Viswatej Avutu, Emily Long Sarro, et al.
Cancer Chemotherapy and Pharmacology
|
October 19, 2010
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Mark A Dickson, Manish A Shah, Dana Rathkopf, et al.
Cancer Medicine
|
June 4, 2021
Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
Anna Lee, Jung J Kang, Havah Bernstein, et al.
Journal of Medical Virology
|
December 12, 2022
Efficacy of immunotherapy with combination of cryotherapy and topical imiquimod for treatment of Kaposi sarcoma
Lilly Gu, Erica Lin, Shuaitong Liu, et al.
Oncogene
|
May 24, 2018
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Mary E Klein, Mark A Dickson, Cristina Antonescu, et al.
Human Pathology
|
December 27, 2014
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P D'Angelo, Alexander N Shoushtari, Narasimhan P Agaram, et al.
Oncology
|
June 6, 2015
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma
Sandra P D'Angelo, Rodrigo R Munhoz, Deborah Kuk, et al.
Oncoimmunology
|
January 4, 2018
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial
David J Chung, Richard D Carvajal, Michael A Postow, et al.
Oncotarget
|
March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Marta Kovatcheva, David D Liu, Mark A Dickson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 77) with videos related to
Sort By:
Page
of 8
Journal of Adolescent and Young Adult Oncology
|
July 15, 2024
Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults
Nicole P Daukshus, Viswatej Avutu, Emily Long Sarro, et al.
Cancer Chemotherapy and Pharmacology
|
October 19, 2010
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
Mark A Dickson, Manish A Shah, Dana Rathkopf, et al.
Cancer Medicine
|
June 4, 2021
Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
Anna Lee, Jung J Kang, Havah Bernstein, et al.
Journal of Medical Virology
|
December 12, 2022
Efficacy of immunotherapy with combination of cryotherapy and topical imiquimod for treatment of Kaposi sarcoma
Lilly Gu, Erica Lin, Shuaitong Liu, et al.
Oncogene
|
May 24, 2018
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Mary E Klein, Mark A Dickson, Cristina Antonescu, et al.
Human Pathology
|
December 27, 2014
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P D'Angelo, Alexander N Shoushtari, Narasimhan P Agaram, et al.
Oncology
|
June 6, 2015
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma
Sandra P D'Angelo, Rodrigo R Munhoz, Deborah Kuk, et al.
Oncoimmunology
|
January 4, 2018
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial
David J Chung, Richard D Carvajal, Michael A Postow, et al.
Oncotarget
|
March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Marta Kovatcheva, David D Liu, Mark A Dickson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
Page
of 8